A phase II study of poziotinib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
DOI: 10.1002/cam4.4231
An open-label expanded access program of afatinib in EGFR tyrosine kinase inhibitor-naïve patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR mutations
DOI: 10.1186/s12885-021-08445-9.
Randomized phase II study of axitinib versus observation in patients with recurred or metastatic adenoid cystic carcinoma
Clin Cancer Res. 2021 Jul 27; clincanres.1061.2021.
Induction Chemotherapy as a Prognostication Index and Guidance for Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma: the Concept of Chemo-Selection (KCSG HN13-01)
Cancer Res Treat. 2021 Apr 27.
Phase II study of durvalumab and tremelimumab in pulmonary sarcomatoid carcinoma: KCSG-LU16-07
Cytokine Volume 142, June 2021, 155487
Outcomes and Biomarkers of Immune Checkpoint Inhibitor Therapy in Patients with Refractory Head and Neck Squamous Cell Carcinoma: KCSG HN18-12
Phase II study of durvalumab and tremelimumab in pulmonary sarcomatoid carcinoma: KCSG-LU16-07
Thorac Cancer. 2020 Dec;11(12):3482-3489
Implications of Tamoxifen Resistance in Palbociclib Efficacy for Patients with Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Subgroup Analyses of KCSG-BR15-10 (YoungPEARL)
Hyperprogressive disease and its clinical impact in patients with recurrent and/or metastatic head and neck squamous cell carcinoma treated with immune-checkpoint inhibitors: Korean cancer study group HN 18-12
J Cancer Res Clin Oncol. 2020 Dec;146(12):3359-3369
Mouse–human co-clinical trials demonstrate superior anti-tumour effects of buparlisib (BKM120) and cetuximab combination in squamous cell carcinoma of head and neck
Br J Cancer. 2020 Dec;123(12):1720-1729.
